Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 87

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 87
---
 or directors to the company, either to fill a position that has become vacant for any reason or as an additional director or directors, provided that the number of directors does not exceed six. Any vacancy, however created (whether by resignation, departure or otherwise, and/or otherwise with respect to any available position of office in case that the number of directors then in office is less than six (6)), shall continue until the next annual ordinary shareholders’ meeting. Subject to the provisions of Swiss law, the board of directors may delegate its powers to the committees of the board of directors, to its CEO, to an officer in the combined company, or to another person. The delegation of authority may be for a specific matter or for a specific period of time, all at the discretion of the board of directors. Further, NLS is a foreign private issuer and, as such, is eligible for an exemption from certain Nasdaq corporate governance requirements that apply to issuers that are not foreign private issuers. A discussion of any material differences in the corporate laws of Israel and Switzerland please see the section entitled “ The Merger Agreement — Governance of the Combined Company after the Merger.” Share Ownership of NLS Directors and Executive Officers As of February27, 2025, NLS’s directors and executive officers as a group, owned and were entitled to vote 577,199 NLS Common Shares, or 17.41% of the outstanding NLS Common Shares. The directors and executive officers have informed us that they intend to vote all of their NLS Common Shares “FOR”the approval of the Merger. Share Ownership of Kadimastem Directors and Executive Officers As of March28, 2025, Kadimastem’s directors and executive officers as a group, owned and were entitled to vote 1,379,829 Kadimastem Ordinary Shares on a fully diluted basis, or 20.1% of the outstanding Kadimastem Ordinary Shares on a fully diluted basis. The Merger has been approved by the shareholders of Kadimastem. Termination of the Merger Agreement (Page 126) The Merger Agreement contains customary termination rights for each of NLS and Kadimastem, including the right of NLS and Kadimastem to terminate the Merger Agreement if the Closing shall not have occurred on or before April30, 2025, which outside date can be extended by mutual agreement. The Merger Agreement also provides that NLS shall pay to Kadimastem a termination fee of $10